Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Anticancer Research|October 3, 2018
Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung CancerShinkichi Takamori, Kazuki Takada, Koichi Azuma, et al.
Annals of Surgery|June 25, 2021
Identification of SLC38A7 as a Prognostic Marker and Potential Therapeutic Target of Lung Squamous Cell CarcinomaNaoki Haratake, Qingjiang Hu, Tatsuro Okamoto, et al.
Journal of Thoracic Disease|March 12, 2026
Relationship between immune-related adverse events and treatment outcome of immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective cohort studyTakafumi Hashimoto, Takashi Karashima, Kosuke Kamada, et al.
Cancer Research Communications|April 15, 2024
Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell CarcinomasAyako Nakashoji, Naoki Haratake, Atrayee Bhattacharya, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 4, 2023
MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLCNaoki Haratake, Hiroki Ozawa, Yoshihiro Morimoto, et al.
Signal Transduction and Targeted Therapy|November 27, 2025
MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancerShinkichi Takamori, Naoki Haratake, Atrayee Bhattacharya, et al.
Oncogene|August 6, 2025
MUC1-C auto-regulatory complex with EBNA1 is responsible for latent Epstein-Barr virus-associated gastric cancer progressionHiroki Ozawa, Yin Wang, Henry G Withers, et al.
JCI Insight|June 24, 2025
MUC1-C dependence in treatment-resistant prostate cancer uncovers a target for antibody-drug conjugate therapyKeisuke Shigeta, Tatsuaki Daimon, Hiroshi Hongo, et al.
NPJ Breast Cancer|April 26, 2025
MUC1-C dependency in drug resistant HR+/HER2- breast cancer identifies a new target for antibody-drug conjugate treatmentAyako Nakashoji, Atrayee Bhattacharya, Hiroki Ozawa, et al.
Molecular Cancer Research : MCR|November 29, 2022
MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast CancerNami Yamashita, Yoshihiro Morimoto, Atsushi Fushimi, et al.
Pageof 12